A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer

•In the setting of Postmastectomy radiation therapy (PMRT) bolus was not proven to reduces the risk of local recurrences.•The use of bolus for PMRT increases the risk of early and late toxicity.•The use of bolus should be limited to highly selected cases, where the skin is deemed to be within the cl...

Full description

Saved in:
Bibliographic Details
Published in:Radiotherapy and oncology 2021-11, Vol.164, p.115-121
Main Authors: Kaidar-Person, Orit, Dahn, Hannah M., Nichol, Alan M., Boersma, Liesbeth J., de Ruysscher, Dirk, Meattini, Icro, Pignol, Jean-Philippe, Aristei, Cynthia, Belkacemi, Yazid, Benjamin, Dori, Bese, Nuran, Coles, Charlotte E., Franco, Pierfrancesco, Ho, Alice Y., Hol, Sandra, Jagsi, Reshma, Kirby, Anna M., Marrazzo, Livia, Marta, Gustavo N., Moran, Meena S., Nissen, Henrik D., Strnad, Vratislav, Zissiadis, Yvonne, Poortmans, Philip M., Offersen, Birgitte V.
Format: Article
Language:English
Subjects:
Bolus
Breast cancer
Breast Neoplasms - radiotherapy
Breast Neoplasms - surgery
Consensus
Delphi Technique
Female
Humans
Mastectomy
PMRT
Radiation therapy
Radiotherapy, Adjuvant
Tissue compensator
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•In the setting of Postmastectomy radiation therapy (PMRT) bolus was not proven to reduces the risk of local recurrences.•The use of bolus for PMRT increases the risk of early and late toxicity.•The use of bolus should be limited to highly selected cases, where the skin is deemed to be within the clinical target volume. Bolus serves as a tissue equivalent material that shifts the 95–100% isodose line towards the skin and subcutaneous tissue. The need for bolus for all breast cancer patients planned for postmastectomy radiation therapy (PMRT) has been questioned. The work was initiated by the faculty of the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer courses and represents a multidisciplinary international breast cancer expert collaboration to optimize PMRT. Due to the lack of randomised trials evaluating the benefits of bolus, we designed a stepwise project to evaluate the existing evidence about the use of bolus in the setting of PMRT to achieve an international consensus for the indications of bolus in PMRT, based on the Delphi method.
ISSN:0167-8140
1879-0887
DOI:10.1016/j.radonc.2021.09.012